BRIEF-Clovis Oncology presents data from phase 2 studies of rucaparib By: Reuters: Company News June 06, 2016 at 08:48 AM EDT * Nineteen patients (9%) discontinued treatment because of an adverse event. Read More >> Related Stocks: Clovis Oncology Inc